[Guidelines for prevention of febrile neutropenia].
Sérgio Girão Barroso(Hospital do Espírito Santo), Inês Moital, Ana Macedo(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto), José Dinis(Instituto Português de Oncologia Francisco Gentil), Helena Gervásio(Instituto Português de Oncologia de Coimbra Francisco Gentil), Margarida Damasceno, José Luís Passos‐Coelho, Anabela Sá, Helena Rodrigues, Sofia Andrade, Ricardo da Luz(Administração Regional de Saúde de Lisboa e Vale do Tejo), Luis Manuel Entrenas Costa(Instituto Maimónides de Investigación Biomédica de Córdoba)
PubMed
September 18, 2008
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
|Annals of Oncology|2017|90
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
|Cancer Chemotherapy and Pharmacology|2014|87